S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Suzuken Net Profit Edges Higher Despite Operating Margin Pressure

Japanese pharmaceutical wholesaler Suzuken Co. Ltd. reported a net profit of ¥31.01 billion for the nine months ended Dec. 31, according to its latest financial filing, narrowly outpacing the previous year’s performance despite a contraction in operating income.

Suzuken Net Profit Edges Higher Despite Operating Margin Pressure

The Nagoya-based distributor saw its revenue climb to ¥1.89 trillion, up from ¥1.84 trillion in the same period a year earlier. This topline growth reflects steady demand within the Japanese healthcare supply chain, though the company’s core profitability metrics showed signs of tightening. Operating profit fell to ¥27.23 billion, a decrease from the ¥29.80 billion reported in the prior year.

Diverging Profitability Metrics

The company’s pretax profit also experienced a year-on-year decline, sliding to ¥29.32 billion from ¥30.91 billion. Despite these pressures on the operating side, Suzuken managed to increase its bottom-line earnings and significantly boost its per-share value. Earnings per share rose to ¥439.74, compared to ¥398.44 in the previous period, according to the company's financial statement.

The results, which are based on Japanese accounting standards, highlight the following key financial shifts for the nine-month period:

    • Total revenue increased to ¥1.89 trillion from ¥1.84 trillion.
    • Operating profit contracted to ¥27.23 billion.
  • Net profit rose to ¥31.01 billion from ¥30.67 billion.
Suzuken’s ability to maintain net profit growth amidst falling operating margins suggests a shift in non-operating income or effective tax management during the fiscal period. The company remains a critical player in Japan’s medical distribution landscape, navigating a market defined by strict pricing regulations and rising logistics costs.
Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!